%PDF-1.4
%
70 0 obj
<>
endobj
67 0 obj
<>
endobj
129 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-05-11T09:47:41Z
2024-03-28T15:26:39-07:00
QuarkXPressª: AdobePS 8.8.0 (301)
2024-03-28T15:26:39-07:00
application/pdf
Heather
2004-686.june
uuid:e0be23d3-1dd1-11b2-0a00-7009277d8900
uuid:e0be23d6-1dd1-11b2-0a00-d30000000000
endstream
endobj
56 0 obj
<>
endobj
57 0 obj
<>
endobj
71 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 38 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 40 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 42 0 R/Type/Page>>
endobj
15 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 44 0 R/Type/Page>>
endobj
18 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 46 0 R/Type/Page>>
endobj
29 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 48 0 R/Type/Page>>
endobj
32 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 50 0 R/Type/Page>>
endobj
155 0 obj
[159 0 R]
endobj
156 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
13.5 787.5 585 -783 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 56.468 737.0293 Tm
[(24.)-875.1 (Carney R, Blumenthal J, Catellier D, et al. Depression as a risk )]TJ
2.175 -1.25 Td
[(factor for mortality after acute myocardial infarction. )54.8 (Am J Cardiol)]TJ
0 Tc 0 Tw 0 -1.25 TD
(2003;92:1277-81.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(25.)-875.1 (Kimmel PL, Peterson RA, )17.7 (W)79.9 (eihs KL, et al. Multiple measurements)]TJ
2.175 -1.25 Td
(of depression predict mortality in a longitudinal study of chronic)Tj
T*
(hemodialysis outpatients. Kidney Int 2000;57:2093-8.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Janzing JG, Bouwens JM, )17.7 (T)69.9 (eunisse RJ, van\325)17.7 (t Hof MA, Zitman FG.)]TJ
2.175 -1.25 Td
(The relationship between depression and mortality in elderly )Tj
T*
(subjects with less severe dementia. Psychol Med 1999;29:979-83.)Tj
-2.175 -1.25 Td
[(27.)-875.1 (Black SA, Markides KS, Ray LA. Depression predicts increased)]TJ
2.175 -1.25 Td
[(incidence of adverse health outcomes in older Mexican )54.8 (Americans)]TJ
T*
(with type 2 diabetes. Diabetes Care 2003;26:2822-8.)Tj
-2.175 -1.25 Td
[(28.)-875.1 (Fries JF)79.7 (, Spitz P)110.7 (, Kraines RG, Holman HR. Measurement of patient)]TJ
2.175 -1.25 Td
[(outcome in arthritis. )54.8 (Arthritis Rheum 1980;23:137-45.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (W)79.9 (olfe F)79.7 (.)-0.1 ( )54.8 (A)-220.1 (reappraisal of HAQ disability in rheumatoid arthritis.)]TJ
2.175 -1.25 Td
(Arthritis Rheum 2000;43:2751-61.)Tj
-2.175 -1.25 Td
[(30.)-875.1 (Meenan RF)79.7 (, Gertman PM, Mason JH, Dunaif R. )17.7 (The )54.8 (Arthritis)]TJ
2.175 -1.25 Td
(Impact Measurement Scales: further investigations of a health )Tj
T*
[(status measure. )54.8 (Arthritis Rheum 1982;25:1048-53.)]TJ
-2.175 -1.25 Td
[(31.)-875.1 (Meenan RF)79.7 (, Gertman PM, Mason JH. Measuring health status in)]TJ
2.175 -1.25 Td
[(arthritis: the )54.8 (Arthritis Impact Measurement Scales. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1980;23:146-52.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(32.)-875.1 (W)79.9 (olfe, F)79.7 (, Michaud K, Gefeller O, Choi HK. Predicting mortality in)]TJ
2.175 -1.25 Td
[(patients with rheumatoid arthritis. )54.8 (Arthritis Rheum )]TJ
0 Tc 0 Tw T*
(2003;48:1530-42.)Tj
0.0249 Tw -2.175 -1.25 Td
[(33.)-875 (Ropes MW)91.8 (, Bennett GA, Cobb S, Jacox R, Jessar RA. 1958 )]TJ
-0.00011 Tc 2.175 -1.25 Td
(revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum)Tj
T*
(Dis 1958;9:175-6.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
2.175 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Blalock SJ, deV)110.8 (ellis RF)79.7 (, Brown GK, )17.7 (W)79.9 (allston KA. )17.7 (V)110.8 (alidity of the)]TJ
2.175 -1.25 Td
(Center for Epidemiological Studies depression scale in arthritis)Tj
T*
[(populations. )54.8 (Arthritis Rheum 1989; 32:991-7.)]TJ
-2.175 -1.25 Td
[(36.)-875.1 (Brown JH, Kazis LE, Spitz PW)91.7 (, Gertman P)110.7 (, Fries JF)79.7 (, Meenan RF)79.7 (.)]TJ
2.175 -1.25 Td
(The dimensions of health outcomes: a cross-validated examination)Tj
T*
[(of health status measurement. )54.8 (Am J Public Health 1984;74:159-61.)]TJ
-2.175 -1.25 Td
[(37.)-875.1 (Mason JH, )54.8 (Anderson JJ, Meenan RF)79.7 (. )54.8 (A)-220.1 (model of health status for)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis: a factor analysis of the )54.8 (Arthritis Impact)]TJ
T*
[(Measurement Scales. )54.8 (Arthritis Rheum 1988;31:714-20.)]TJ
-2.175 -1.25 Td
[(38.)-875.1 (Mitz B, Mantenach CA, Himmel J, Black J, Munz C, Lightfoot)]TJ
2.175 -1.25 Td
[(R)54.8 (W)91.9 (. )54.8 (A)-220.1 (comparison of psychosocial and physical tests in rheumatoid)]TJ
T*
[(arthritis [abstract]. )54.8 (Arthritis Rheum 1983;26 Suppl:S148.)]TJ
-2.175 -1.25 Td
[(39.)-875.1 (Potts MK, Brandt KD. Evidence of the validity of the )54.8 (Arthritis)]TJ
2.175 -1.25 Td
[(Impact Measurement Scales. )54.8 (Arthritis Rheum 1987;30:93-6.)]TJ
-2.175 -1.25 Td
[(40.)-875.1 (Choi HK, Hernan MA, Seeger JD, Robins JM, )17.7 (W)79.9 (olfe F)79.7 (.)]TJ
2.175 -1.25 Td
(Methotrexate therapy and mortality in patients with rheumatoid)Tj
T*
[(arthritis: a prospective study)64.8 (. Lancet 2002;359:1)36.8 (173-7.)]TJ
-2.175 -1.25 Td
[(41.)-875.1 (W)79.9 (olfe F)79.7 (, Hawley DJ. )17.7 (The relationship between clinical activity and)]TJ
2.175 -1.25 Td
(depression in rheumatoid arthritis. J Rheumatol 1993;20:2032-7.)Tj
-2.175 -1.25 Td
[(42.)-875.1 (Pincus )17.7 (T)74 (, Callahan LF)79.7 (, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ.)]TJ
2.175 -1.25 Td
(Self-report questionnaire scores in rheumatoid arthritis compared)Tj
T*
(with traditional physical, radiographic and laboratory measures.)Tj
T*
[(Ann Intern Med 1989;1)36.8 (10:259-66.)]TJ
-2.175 -1.25 Td
[(43.)-875.1 (Callahan LF)79.7 (, Pincus )17.7 (T)74 (, Huston JW)-257.3 (III, Brooks RH, Nance EP)-238.2 (Jr)39.7 (,)]TJ
2.175 -1.25 Td
(Kaye JJ. Measures of activity and damage in rheumatoid arthritis:)Tj
T*
(Depiction of changes and prediction of mortality over five years.)Tj
T*
(Arthritis Care Res 1997;10:381-94.)Tj
-2.175 -1.25 Td
[(44.)-875.1 (Allebeck P)110.7 (. Increased mortality in rheumatoid arthritis. Scand )]TJ
2.175 -1.25 Td
[(J Rheumatol 1982;1)36.8 (1:81-6.)]TJ
-2.175 -1.25 Td
[(45.)-875.1 (Symmons DP)110.7 (, Jones MA, Scott DL, Prior P)110.7 (. Longterm mortality)]TJ
2.175 -1.25 Td
(outcome in patients with rheumatoid arthritis: early presenters )Tj
T*
(continue to do well. J Rheumatol 1998;25:1072-7.)Tj
-2.175 -1.25 Td
[(46.)-875.1 (W)79.9 (olfe F)79.7 (, Mitchell DM, Sibley JT)73.9 (, et al. )17.7 (The mortality of rheumatoid)]TJ
2.175 -1.25 Td
[(arthritis. )54.8 (Arthritis Rheum 1994;37:481-94.)]TJ
30.825 80 Td
[(47.)-875.1 (Husaini BA, Nef)17.7 (f JA, Harrington JB, Hughes MD, Stone RH.)]TJ
2.175 -1.25 Td
(Depression in rural communities: validating the CES-D scale. )Tj
T*
(J Community Psychol 1980;8:20-7.)Tj
-2.175 -1.25 Td
[(48.)-875.1 (Kinder LS, Kamarck )17.7 (TW)91.7 (, Baum )54.8 (A, Orchard )17.7 (TJ. Depressive )]TJ
2.175 -1.25 Td
[(symptomatology and coronary heart disease in )17.7 (T)69.9 (ype 1 diabetes )]TJ
T*
(mellitus: a study of possible mechanisms. Health Psychol)Tj
0 Tc 0 Tw T*
(2002;21:542-52.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(49.)-875.1 (Penninx BW)91.7 (, Kritchvevsky SB, )36.8 (Y)99.8 (a)0.3 (f)17.7 (fe K, et al. Inflammatory )]TJ
2.175 -1.25 Td
(markers and depressed mood in older persons: results from the)Tj
0 Tc T*
[(Health, )54.8 (Aging and Body Composition study)64.9 (. Biol Psychiatry)]TJ
0 Tw T*
(2003;54:566-72.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(50.)-875.1 (Fortes C, Farchi S, Forastiere F)79.7 (, et al. Depressive symptoms lead to)]TJ
2.175 -1.25 Td
(impaired cellular immune response. Psychother Psychosom)Tj
0 Tc 0 Tw T*
(2003;72:253-60.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(51.)-875.1 (Cakirbay H, Bilici M, Kavakci O, Cebi )54.8 (A, Guler M, )17.7 (T)69.9 (an U. Sleep)]TJ
2.175 -1.25 Td
(quality and immune functions in rheumatoid arthritis patients with)Tj
T*
[(and without major depression. Int J Neurosci 2004;1)36.8 (14:245-56.)]TJ
-2.175 -1.25 Td
[(52.)-875.1 (Ciechanowski PS, Katon )17.7 (WJ, Russo JE. Depression and diabetes:)]TJ
2.175 -1.25 Td
(impact of depressive symptoms on adherence, function and costs.)Tj
T*
(Arch Intern Med 2000;160:3278-85.)Tj
-2.175 -1.25 Td
[(53.)-875.1 (Ramasubbu R. Insulin resistance: a metabolic link between )]TJ
2.175 -1.25 Td
(depressive disorder and atherosclerotic vascular diseases. Med)Tj
T*
(Hypotheses 2002;59:537-51.)Tj
-2.175 -1.25 Td
[(54.)-875.1 (Lederbogen F)79.7 (, Gilles M, Maras )54.8 (A, et al. Increased platelet )]TJ
2.175 -1.25 Td
(aggregability in major depression? Psychiatry Res )Tj
0 Tc 0 Tw T*
(2001;102:255-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(55.)-875.1 (Musselman DL, )17.7 (T)69.9 (omer )54.8 (A, Manatunga )54.8 (AK, et al. Exaggerated)]TJ
2.175 -1.25 Td
[(platelet reactivity in major depression. )54.8 (Am J Psychiatry)]TJ
0 Tc 0 Tw T*
(1996;153:1313-7.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(56.)-875.1 (Pincus )17.7 (T)74 (,)-0.1 ( Keysor J, Sokka )17.7 (T)74 (, Krishnan E, Callahan L. Patient )]TJ
2.175 -1.25 Td
(questionnaires and formal education level as prospective predictors)Tj
T*
(of mortality over 10 years in 97% of 1416 patients with rheumatoid)Tj
T*
(arthritis from 15 United States private practices. J Rheumatol)Tj
0 Tc 0 Tw T*
(2004;31:229-34.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(57.)-875.1 (Memel DS, Kirwan JR, Sharp DJ, Hehir M. General practitioners)]TJ
2.175 -1.25 Td
(miss disability and anxiety as well as depression in their patients)Tj
T*
(with osteoarthritis. Br J Gen Pract 2000;50:645-8.)Tj
-2.175 -1.25 Td
[(58.)-875.1 (Kessler D, Lloyd K, Lewis G, Gray DP)110.7 (. Cross sectional study of)]TJ
2.175 -1.25 Td
(symptom attribution and recognition of depression and anxiety in)Tj
T*
(primary care. BMJ 1999;318:436-9.)Tj
-2.175 -1.25 Td
[(59.)-875.1 (Garrard J, Rolnick SJ, Nitz NM, et al. Clinical detection of )]TJ
2.175 -1.25 Td
(depression among community based elderly people with )Tj
T*
(self-reported symptoms of depression. J Gerontol )Tj
0 Tc 0 Tw T*
(1998;53A:M92-101.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(60.)-875.1 (Pignone MP)110.7 (, Gaynes BN, Rushton JL, et al. Screening for )]TJ
2.175 -1.25 Td
(depression in adults: a summary of the evidence for the U.S.)Tj
T*
[(Preventive Services )17.7 (T)69.9 (ask Force. )54.8 (Ann Intern Med 2002;136:765-76.)]TJ
-2.175 -1.25 Td
[(61.)-875.1 (Keller MB. Depression: underrecognition and undertreatment by)]TJ
2.175 -1.25 Td
[(psychiatrists and other health care professionals. )54.8 (Arch Intern Med)]TJ
0 Tc 0 Tw T*
(1990;150:946-8.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(62.)-875.1 (Hirschfeld RMA, Keller MB, Panico S, et al. )17.7 (The National)]TJ
2.175 -1.25 Td
[(Depressive and Manic-Depressive )54.8 (Association consensus statement)]TJ
T*
[(on the undertreatment of depression. JAMA)-220.2 (1997;277:333-40.)]TJ
-2.175 -1.25 Td
[(63.)-875.1 (W)79.9 (ells KB, Hays RD, Burnam MA, Rogers )17.7 (W)91.8 (, Greenfield S, )17.7 (W)79.9 (are)]TJ
2.175 -1.25 Td
[(JE Jr)54.8 (. Detection of depressive disorder for patients receiving )]TJ
T*
[(prepaid or fee-for)19.7 (-service care: results from the Medical Outcomes)]TJ
0 Tc T*
[(Study)64.9 (. JAMA)-220.1 (1989;262:3298-302.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(64.)-875.1 (O\325Malley PG, Jackson JL, Kroenke K, )36.8 (Y)99.8 (oon IK, Hornstein E,)]TJ
2.175 -1.25 Td
[(Dennis GL. )17.7 (The value of screening for psychiatric disorders in)]TJ
T*
[(rheumatology referrals. )54.8 (Arch Intern Med 1998;158:2357-62.)]TJ
-2.175 -1.25 Td
[(65.)-875.1 (Parker J, Smarr K, Slaughter J, et al. Management of depression in)]TJ
2.175 -1.25 Td
[(rheumatoid arthritis: )54.8 (A)-220.1 (combined pharmacologic and )]TJ
T*
[(cognitive-behavioral approach. )54.8 (Arthritis Care Res 2003;49:766-77.)]TJ
ET
0 0 0 1 K
53.468 76.5 m
558.468 76.5 l
S
0 0 0 0 k
494.29 69.365 64.178 -15.665 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
0 Tc 0 Tw 8 0 0 8 541.468 56.4344 Tm
(1019)Tj
-0.00011 Tc 0.02499 Tw -60.867 -0.0144 Td
[(Ang, et al: Comorbid depr)36.8 (ession in RA)]TJ
ET
0 0 0 0 k
/GS0 gs
104.631 82.25 407.5 -10.833 re
f*
0.5 w
/GS1 gs
104.631 82.25 407.5 -10.833 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_2 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_3 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
50 0 obj
<>stream
8;Z]!JT@8G$q(!n5Nq!=kADS1K/pFuggiJ!1^jQJou`Gfbhr(8Xbcb!a`u\,p\Cfj
;U=BC\)O9$cV0DcqKVrAEitacA7K23oqHOEp+l&?f+SY.[n&q[efE`LT^IW$2f.^tmh-XAsUjd5lY*CSL_@f)5B\3YnE&E_&NO%o[q$:'KpG_3K0D5
e9<*VPiHL(^1gr?PU@V<^/\?6!_cDccEXl+0SDgAuf`&
pi1?[9I#.@[s10!hG_XSQQPRHq'lcT6"nAjfY_^"&R-W/\P]?G)BjE`=_._AbY72X(Br990O.UmPIT%o=-H9Q8:
U9^[ok*?U$mWiJ%QCH3U6k_0ajI[3M-]siAhatj&[oWLrMD)'K,[]C,Y.D4=^8okX
e>D-rZdt`L!*NMc[K~>
endstream
endobj
54 0 obj
[/Indexed/DeviceRGB 255 53 0 R]
endobj
53 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
82 0 obj
<>
endobj
77 0 obj
<>
endobj
114 0 obj
<>
endobj
134 0 obj
<>
endobj
76 0 obj
<>
endobj
107 0 obj
<>stream
HtUkPWfApi[Qʰ5SG^@D^2"yHxB|nV+e*Ѭ-_9M[ɟڭ[uֹ;s]"Hg특A(ꤰX]ĸ%$gRf%
њjg% v~YI_:D
As> 4n$qNkȄ(qS1)*(H0aIQEqyl8(FɲݍEQaQqa1!Z\OHJGŰ Q'H]AeK>Aʃ!Vd[b-1$< bXD bXKGr
A~B\%TɪGET%M2DBG5lml m;.oz⎉j?u}I&};9Tjj9M)bm zG!7S:բ8:#5E9삅Y[ggj/^bveUP,E>6xPU,[Ű=L>5j#rMhj~':nݡRB:yY`owpZw0,?=_㢃S#
hOYL3Rb6(&P(UgS=5